TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alphamab Oncology ( (HK:9966) ) has provided an announcement.
Alphamab Oncology announced that its drug JSKN003 has received approval from the U.S. FDA to begin a phase II clinical study for treating platinum-resistant ovarian cancer not restricted by HER2 expression. This approval is a significant milestone in Alphamab’s global development strategy, enhancing its competitive position in oncology therapeutics. The study will assess the safety and efficacy of JSKN003, a biparatopic HER2-targeting antibody-drug conjugate, and determine the recommended phase III dose. This development is expected to strengthen Alphamab’s innovative pipeline and impact its stakeholders positively.
More about Alphamab Oncology
Alphamab Oncology is a leading biopharmaceutical company in China, specializing in antibody-drug conjugates (ADCs), bispecific antibodies, and multi-functional protein engineering. The company has developed a proprietary technology platform and a highly differentiated pipeline of oncology therapeutics, including ADCs, monoclonal antibodies, and bispecific antibodies, with one product approved for marketing in China and several others in advanced clinical trial stages.
Average Trading Volume: 4,214,814
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.98B
Learn more about 9966 stock on TipRanks’ Stock Analysis page.